About the Company
nkarta therapeutics seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies. nkarta was founded on the proprietary, robust and well characterized natural killer (nk) cell expansion technology pioneered by dario campana. the company is focused on leveraging the natural potent power of nk cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. nkarta is combining its nk expansion platform technology with proprietary cell engineering technologies to build differentiated autologous and allogeneic cell therapy candidates for the treatment of cancer. founded in 2015, the company’s investors include sr one, nea and novo ventures. for more information, please visit the company’s website at www.nkartatx.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NKTX News
Nkarta Prices $240 Mln Offering; Stock Up Over 16%
Nkarta, Inc. (NKTX), a biopharmaceutical firm focused on engineered natural killer cell therapies, on Monday announced that it has ...
Nkarta Announces Pricing of $240 Million Underwritten Offering
Gross proceeds to Nkarta from this offering are approximately $240.1 million, before deducting underwriting discounts and commissions and offering expenses. Nkarta intends to use the net proceeds from ...
Nkarta: NK Cell Therapy Advancement On Two Fronts
Nkarta had $250.9 million in cash as of December 31, 2023, to fund its operations into 2026. Despite this cash runway, a ...
Nkarta (NASDAQ: NKTX)
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product ...
Nkarta announces pricing of stock offering to raise $240.1M
Nkarta (NASDAQ:NKTX) announces the pricing of an underwritten offering of 21.01 million shares of its common stock for $10.00 per share and pre-funded warrants to purchase 3 million shares of common ...
Nkarta Inc (NKTX) Posts Full Year 2023 Financial Results: A Focus on NKX019 and Pipeline Realignment
Prioritization of NKX019 for autoimmune diseases, with the first patient dosing expected in the first half of 2024. Pipeline Realignment: Deprioritization of NKX101 development following a review of ...
Nkarta, Inc.: Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
March 21, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results ...
Nkarta Announces Pricing of $240 Million Underwritten Offering
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced ...
Nkarta Prices $240 Mln Offering; Stock Up Over 16%
(RTTNews) - Nkarta, Inc. (NKTX), a biopharmaceutical firm focused on engineered natural killer cell therapies, on Monday announced that it has priced an offering of 21,010,000 shares at $10 per ...
Loading the latest forecasts...